MedTrace Logo

Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes

NCT06838286 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 10000

Last updated 2025-02-20

No results posted yet for this study

Summary

A multicenter, prospective, non-interventional observation study to evaluate the safety and effectiveness of OAD triple therapy in Korean Type 2 diabetic mellitus patients.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

SGLT2 inhibitor

SGLT2 inhibitor class of drugs

DRUG

Thiazolidinedione

Thiazolidinedione class of drugs

DRUG

DPP-4 inhibitor

DPP4 inhibitor class of drugs

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-16
Primary Completion
2026-12-31
Completion
2029-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06838286 on ClinicalTrials.gov